BioSpace News Archive

Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.

The companies will design and develop targeted gene therapies for a liver-directed rare disease program and conduct additional studies for central nervous system-directed rare disease programs.

GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 2:50 p.m. ET (11:50 a.m. PT).

DJO® announced it will showcase their growing Foot & Ankle offerings at the 2022 American College of Foot and Ankle Surgeons Scientific Conference in Austin from February 21-24, 2022.

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will deliver a corporate presentation during the Sachs 15th Annual European Life Sciences CEO Forum taking place virtually March 1-2, 2022.

Arima Genomics, Inc., the leader in 3D genomics, today announced the launch of new solutions for structural variant detection and gene regulation analysis.

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor OPDIVO and YERVOY, in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer.

Neuronetics, Inc. announced it has amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment Corp., which was originally entered into on March 2, 2020 and subsequently amended on April 20, 2020 and December 2, 2020.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42nd Annual Health Care Conference.